BioSpace News Archive

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new positive data from the Phase 1 investigator-sponsored trial of INB-100 in leukemia patients.

Enzo Biochem, Inc. announced that its special meeting of shareholders to consider and vote on a proposal to approve the sale of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Labcorp and adopt the Asset Purchase Agreement, dated as of March 16, 2023, by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced that Janux management will participate at two upcoming investor conferences and be available for 1x1 meetings.

LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

Baudax Bio, Inc. announced the Company is hosting a virtual key opinion leader event Innovation in Anesthesia: BX1000 for Neuromuscular Blockade featuring Dr. Todd M. Bertoch, Chief Executive Officer of JBR Clinical Research, and Dr. Harold S. Minkowitz, Associate Director for Clinical Research at The University of Texas MD Anderson Cancer Center Department of Anesthesiology and Perioperative Medicine.

Owens & Minor, Inc. plans to release financial results for the first quarter of 2023 on Friday, May 5, 2023, before trading begins on the New York Stock Exchange.

SRI International, an independent nonprofit research institute behind countless cutting-edge technological advances, announced it will receive the Palo Alto Research Center, a Xerox company and technology pioneer.

Samsung Bioepis Co., Ltd. today announced that 1-year outcomes of the Phase 3 study for SB15, a proposed biosimilar to Eylea1(aflibercept), were presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from April 23 to 27, in New Orleans, Louisiana.

Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 fourth quarter and full year financial results at 9:00 a.m. ET on May 11, 2023.